ArticleScientific reports2026
Chicken biliary exosomes ameliorate lipopolysaccharide-induced hepatocyte injury.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Investigate the protective effects of chicken bile-derived exosomes (CB-exos) against lipopolysaccharide (LPS)-induced acute hepatocyte injury. CB-exos were characterized by transmission electron microscopy observation and Western blotting. Subsequently, after 24 h of CB-exos treatment, the levels of alanine transaminase (ALT) and aspartate transaminase (AST) in the hepatocyte culture supernatant and chicken serum were measured using specific test kits. The morphology of hepatocytes was observed under a microscope. Additionally, quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to detect the expression levels of inflammatory cytokines, apoptosis-related proteins, and hepatocyte growth factors. CB-exos exhibited a typical cup-shaped morphology with an average diameter 50-100 nm, and the exosomal marker Tsg-101 was successfully detected. Treatment with CB-exos significantly reduced the concentrations of ALT and AST in the supernatant and chicken serum. Microscopic examination revealed the emergence of newly divided hepatocyte clusters. In liver tissues, CB-exos effectively mitigated the inflammatory response, with areas previously affected by inflammation being replaced by regenerating hepatocytes. Furthermore, CB-exos significantly down-regulated the expression of TNF-α, IL-6, iNOS, caspase-3 and Bax in damaged hepatocytes and liver tissues. Conversely, the expression levels of the Bcl-2 and hepatocyte growth factors (HGF) were markedly increased. CB-exos possess the capacity to alleviate hepatocyte injury and promote cell division and regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.